Skip to main content
SpringerLink
Log in

Adrenal Carcinoma – Radionuclide Imaging

  • Chapter
Book cover Imaging in Oncological Urology

  • 1350 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kloos RT, Gross MD, Shapiro B, Francis IR, Korobkin M, Thompson NW. Diagnostic dilemma of small incidentally discovered adrenal masses: role for 131I-6beta-iodomethyl-norcholesterol scintigraphy. World J Surg. 1997;21(1):36–40.

    Article  Google Scholar 

  2. Thompson GB, Young WF, Jr. Adrenal incidentaloma. Curr Opin Oncol. 2003;15(1):84–90.

    Article  Google Scholar 

  3. Zarco-Gonzalez JA, Herrera MF. Adrenal incidentaloma. Scand J Surg. 2004;93(4):298–301.

    Google Scholar 

  4. Third nationalcancer survey: incidence data. DHEW Publishers No (NIH) 75–787 NCI monograph. Bethesda: National Cancer Institute; 1975. p. 41.

    Google Scholar 

  5. Dackiw AP, Lee, JE, Gagel RF, Evans DB. Adrenal Cortical Carcinoma. World J Surg 2001;25(7):914–926.

    Article  Google Scholar 

  6. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000;88(4):711–36.

    Article  Google Scholar 

  7. Beierwaltes WH, Lieberman LM, Ansari AN, Nishiyama H. 131 I-19-iodocholesterol in the diagnosis of adrenal disease. J Lab Clin Med. 1971;78(6):986–7.

    Google Scholar 

  8. Lieberman LM, Beierwaltes WH, Conn JW, Ansari AN, Nishiyama H. Diagnosis of adrenal disease by visualization of human adrenal glands with 131 I-19-iodocholesterol. N Engl J Med. 1971;285(25):1387–93.

    Google Scholar 

  9. Conn JW, Cohen EL, Lucas CP, et al. Visualization of aldosterone-producing tumors (APT) by scintillation scanning (SS) employing tracer amounts of 131 -iodocholesterol. J Lab Clin Med. 1971;78(5):814–5.

    Google Scholar 

  10. Counsell RE, Ranade VV, Blair RJ, Beierwaltes WH, Weinhold PA. Tumor localizing agents. IX. Radioiodinated cholesterol. Steroids. 1970;16(3):317–28.

    Article  Google Scholar 

  11. Sarkar SD, Beierwaltes H, Ice RD, et al. A new and superior adrenal scanning agent, NP-59. J Nucl Med. 1975;16(11):1038–42.

    Google Scholar 

  12. Sarkar SD, Ice RD, Beierwaltes WH, Gill SP, Balachandran S, Basmadjian GP. Selenium-75-19-selenocholesterol-a new adrenal scanning agent with high concentration in the adrenal medulla. J Nucl Med. 1976;17(3):212–7.

    Google Scholar 

  13. Freeman DA, Counsell RE. Cellular internalization, transport, and esterification of iodine-125-NP59 by MA-10 Leydig tumor cells. J Nucl Med. 1991;32(3):495–9.

    Google Scholar 

  14. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrinol. 2002;147(1):13–28.

    Article  Google Scholar 

  15. Harbert JC. The adrenal glands and neural crest tumors. In: Harbert JC, Eckelman WC, Neumann RD, editors. Nuclear medicine: diagnosis and therapy. New York: Thieme Medical Publishers; 1996. pp. 745–58.

    Google Scholar 

  16. Warburg O. The metabolism of tumors. London: Constable Press; 1930.

    Google Scholar 

  17. Patronas NJ, Brooks RA, DeLaPaz RL, Smith BH, Kornblith PL, Di Chiro G. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR Am J Neuroradiol. 1983;4(3):533–5.

    PubMed  CAS  Google Scholar 

  18. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987;28(5):910–4.

    PubMed  CAS  Google Scholar 

  19. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28(3):288–92.

    PubMed  CAS  Google Scholar 

  20. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology. 1989;170(2):329–32.

    PubMed  CAS  Google Scholar 

  21. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15(2):61–6.

    Article  PubMed  CAS  Google Scholar 

  22. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med. 1997;27(2):94–106.

    Google Scholar 

  23. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999;40(4):591–603.

    PubMed  CAS  Google Scholar 

  24. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med. 1999;40(10):1706–15.

    PubMed  CAS  Google Scholar 

  25. Erasmus JJ, Patz EF, Jr., McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168(5):1357–60.

    PubMed  CAS  Google Scholar 

  26. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42(12):1795–9.

    PubMed  CAS  Google Scholar 

  27. Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45(12):2058–62.

    PubMed  Google Scholar 

  28. Frilling A, Tecklenborg K, Weber F, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery, 2004;136(6):1289–96.

    Article  PubMed  Google Scholar 

  29. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;194(1):131–4.

    PubMed  CAS  Google Scholar 

  30. Maurea S, Mainolfi C, Bazzicalupo L, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol. 1999;173(1):25–9.

    PubMed  CAS  Google Scholar 

  31. Maurea S, Caraco C, Klain M, Mainolfi C, Salvatore M. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Q J Nucl Med Mol Imaging. 2004;48(3):188–97.

    PubMed  CAS  Google Scholar 

  32. Becherer A, Vierhapper H, Potzi C, et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm. 2001;16(4):289–95.

    Article  PubMed  CAS  Google Scholar 

  33. Kreissig R, Amthauer H, Krude H, et al. The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol. 2000;30(5):306.

    Google Scholar 

  34. Beierwaltes WH, Wieland DM, Ice RD, et al. Localization of radiolabeled enzyme inhibitors in the adrenal gland. J Nucl Med. 1976;17(11):998–1002.

    PubMed  CAS  Google Scholar 

  35. Beierwaltes WH, Wieland DM, Mosley ST, et al. Imaging the adrenal glands with radiolabeled inhibitors of enzymes: concise communication. J Nucl Med. 1978;19(2):200–3.

    PubMed  CAS  Google Scholar 

  36. Bergstrom M, Bonasera TA, Lu L, et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998;39(6):982–9.

    PubMed  CAS  Google Scholar 

  37. Robien W, Zolle I. Synthesis of radioiodinated metyrapone – a potential adrenal imaging agent. Int J Appl Radiat Isot. 1983;34(6):907–14.

    Article  PubMed  CAS  Google Scholar 

  38. Damani LA, Mitterhauser M, Zolle I, Lin G, Oehler E, Ho YP. Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology. Nucl Med Biol. 1995;22(8):1067–74.

    Article  PubMed  CAS  Google Scholar 

  39. Bergstrom M, Juhlin C, Bonasera TA, et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med. 2000;41(2):275–82.

    PubMed  CAS  Google Scholar 

  40. Khan TS, Sundin A, Juhlin C, Langstrom B, Bergstrom M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30(3):403–10.

    PubMed  Google Scholar 

  41. Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. 11C-metomidate positron emission tomography of adrenocortical tumours in correlation with histopathological findings. J Clin Endocrinol Metab. 2006;91(4):1410–1414.

    Article  PubMed  CAS  Google Scholar 

  42. Zettinig G, Mitterhauser M, Wadsak W, et al. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging. 2004;31(9):1224–30.

    Article  PubMed  Google Scholar 

  43. Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab. 2006;91(4):1410–4.

    Article  PubMed  CAS  Google Scholar 

  44. Wadsak W, Mitterhauser M. Synthesis of [18F]FETO, a novel potential 11-beta hydroxylase inhibitor. J Labelled Comp Radiopharm. 2003;46(4):379–88.

    Article  CAS  Google Scholar 

  45. Mitterhauser M, Wadsak W, Wabnegger L, et al. In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats. Eur J Nucl Med Mol Imaging. 2003;30(10):1398–401.

    Article  PubMed  CAS  Google Scholar 

  46. Wadsak W, Mitterhauser M, Rendl G, et al. [(18)F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging. 2006;33(6):669–672.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Landeskrankenhaus Feldkirch, Carinagasse 47, A-6807 Feldkirch, Austria

    A. Becherer

  2. Department of Nuclear Medicine, Medical University of Vienna, Vienna, Austria

    G. Karanikas MD, M. Mitterhauser PhD, W. Wadsak PhD, G. Zettinig MD & G. Rendl MD

Authors
  1. A. Becherer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Karanikas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Mitterhauser PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Wadsak PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Zettinig MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Rendl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Academic Medical Center, Amsterdam, The Netherlands

    Jean J.M.C.H. de la Rosette  & Hessel Wijkstra  & 

  2. Department of Urology, The George Washington University, Washington, USA

    Michael J. Manyak

  3. Department of Radiology, Massachusetts General Hospital, Boston, DC, USA

    Mukesh G. Harisinghani

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Becherer, A., Karanikas, G., Mitterhauser, M., Wadsak, W., Zettinig, G., Rendl, G. (2009). Adrenal Carcinoma – Radionuclide Imaging. In: de la Rosette, J.J., Manyak, M.J., Harisinghani, M.G., Wijkstra, H. (eds) Imaging in Oncological Urology. Springer, London. https://doi.org/10.1007/978-1-84628-759-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-759-6_3

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-514-1

  • Online ISBN: 978-1-84628-759-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation